3 weeks BioCryst Pharmaceuticals (BCRX) Reports Q3 Loss, Tops Revenue EstimatesZacks
BioCryst (BCRX) delivered earnings and revenue surprises of 0% and 2.01%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
X